CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best ARK Stocks to Buy Right Now.

On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch. The company reported a net loss of $122.9 million for Q1 2026, lower than $136.0 million a year earlier. R&D expenses dipped to $68.6 million from $72.5 million, and G&A costs to $17.2 million from $19.3 million, the company said. Most importantly, its cash position actually strengthened, going up to $2.44 billion as of March 31, 2026, from $1.98 billion at the year’s end of 2025.

The company reported that CRISPR Therapeutics AG (NASDAQ:CRSP)’s CASGEVY had $43 million in revenue, with more than 500 patients having treatment worldwide.

CEO Samarth Kulkarni said the quarter showed “continued execution,” pointing out expanded Zugo Cel programs and continuous momentum for CASGEVY. He added that the corporation believes 2026 “will be a defining year,” noting multiple upcoming milestones.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm that works on the development of Crispr/Cas9-based therapies.

While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1